Home » FOREST LABORATORIES, ALMIRALL ENTER INTO DEAL TO COLLABORATE ON DEVELOPMENT AND MARKETING OF NEW COPD DRUG
FOREST LABORATORIES, ALMIRALL ENTER INTO DEAL TO COLLABORATE ON DEVELOPMENT AND MARKETING OF NEW COPD DRUG
Monday morning, Forest Laboratories Inc., a New-York based pharmaceutical company, revealed that its subsidiary, Forest Laboratories Holdings Ltd., entered into a deal with Almirall, a Spain-based pharmaceutical company for the joint development and distribution of Almirall-developed, inhaled, long-acting muscarinic antagonist, LAS34273, in the United States.
Trading
Markets
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May